Cognitive Impairment in Alzheimer’s and Metabolic Diseases: A Catecholaminergic Hypothesis DOI
Kioko Guzmán‐Ramos, Daniel Osorio‐Gómez, Federico Bermúdez‐Rattoni

и другие.

Neuroscience, Год журнала: 2022, Номер 497, С. 308 - 323

Опубликована: Май 30, 2022

Язык: Английский

(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression DOI Creative Commons

Xingming Wang,

Jianjun Yang, Kenji Hashimoto

и другие.

Neuroscience & Biobehavioral Reviews, Год журнала: 2022, Номер 139, С. 104762 - 104762

Опубликована: Июнь 30, 2022

Neurological disorders are the leading cause of disability and second death worldwide. The increasing social economic burdens neurological driven by global population growth aging. Depression is a common psychiatric symptom in numerous disorders. It also risk factor for Alzheimer's disease (AD) other dementias, Parkinson's (PD), stroke. rapid-acting sustained antidepressant actions (R,S)-ketamine severe depression was accidentally discovered. Interestingly, (R)-ketamine has greater potency longer-lasting antidepressant-like effects than (S)-ketamine rodents. Importantly, its side rodents humans lower those (S)-ketamine. Furthermore, could elicit beneficial various rodent models disorders, including PD, multiple sclerosis (MS), In this article, we review potential as prophylactic or therapeutic drug AD MS,

Язык: Английский

Процитировано

41

The Effects of SARS-CoV-2 Infection on the Cognitive Functioning of Patients with Pre-Existing Dementia DOI Creative Commons
Souvik Dubey, Shambaditya Das, Ritwik Ghosh

и другие.

Journal of Alzheimer s Disease Reports, Год журнала: 2023, Номер 7(1), С. 119 - 128

Опубликована: Фев. 2, 2023

Background: Cognitive postscripts of COVID-19, codenamed as ‘cognitive COVID’ or ‘brain fog,’ characterized by multidomain cognitive impairments, are now being reckoned the most devastating sequelae COVID-19. However, impact on already demented brain has not been studied. Objective: We aimed to assess functioning and neuroimaging following SARS-CoV-2 infection in patients with pre-existing dementia. Methods: Fourteen COVID-19 survivors dementia (four Alzheimer’s disease, five vascular dementia, three Parkinson’s disease two behavioral variant frontotemporal dementia) were recruited. All these had detailed evaluations within months before suffering from one year later. Results: Of 14 patients, ten required hospitalization. developed increased white matter hyperintensities that mimicked multiple sclerosis small vessel disease. There was a significant increase fatigue ( p = 0.001) depression 0.016) scores The mean Frontal Assessment Battery (p < Addenbrooke’s Examination also significantly worsened. Conclusion: rapid progression addition further impairments/deterioration abilities, new appearance lesion burden suggest previously compromised brains have little defense withstand insult (i.e., ‘second hit’ like infection/dysregulated immune response, inflammation). ‘Brain fog’ is an ambiguous terminology without specific attribution spectrum post-COVID-19 sequelae. propose codename, i.e. ‘FADE-IN MEMORY’ Fatigue, decreased Fluency, Attention deficit, Depression, Executive dysfunction, slowed INformation processing speed, subcortical MEMORY impairment).

Язык: Английский

Процитировано

36

Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment DOI
Yu‐Yuan Huang,

Yi‐Han Gan,

Yang Liu

и другие.

Biological Psychiatry, Год журнала: 2023, Номер 95(11), С. 992 - 1005

Опубликована: Окт. 20, 2023

Язык: Английский

Процитировано

32

Effects of adverse childhood health experiences on cognitive function in Chinese middle-aged and older adults: mediating role of depression DOI Creative Commons

Gaoling Wang,

Yuqin Zhou,

Jing Duan

и другие.

BMC Public Health, Год журнала: 2023, Номер 23(1)

Опубликована: Июль 5, 2023

Abstract Background Adverse childhood experiences are critical factors in depression and cognitive decrease, but the effect of adverse health (ACHEs) on function role have not been fully studied. Methods Data were taken from China Health Retirement Longitudinal Study (CHARLS) 2014 2018. This study used indicators situational memory ability mental status to measure capacity. Besides analyzing different types ACHEs, scores for ACHEs calculated represent severity ACHEs. The Center Epidemiologic Studies Depression Scale (CES-D) was assess depression. analysis this employed two analytical strategies order examine mediated effects We Sobel’s test Baron Kenny’s causal step approach, which utilized a generalized least squares regression model. Furthermore, logistic model evaluate robustness Karlson-Holm-Breen (KHB) approach. Results In study, 6301 individuals who met requirements included. found that being confined bed (ACHE3) (β=-0.3846, p = 0.022) had negative impact function. Similarly, (β=-0.0819, 0.090). And after introduced into model, coefficient no longer significant (β=-0.0170, 0.727). Sobel showed ACHE3, proportion total 36.92%. While 70.11%. Finally, mediating using KHB method revealed still existed. Further, based gender, age, educational levels, heterogeneity indicated relationship between as well passing interaction. Conclusion decline cognition shown be correlated with relationship. Positive interventions might help improve performance suffering

Язык: Английский

Процитировано

31

Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders DOI Creative Commons
Javier Pagonabarraga, Cecilio Álamo, Mar Castellanos

и другие.

Brain Sciences, Год журнала: 2023, Номер 13(2), С. 318 - 318

Опубликована: Фев. 13, 2023

Depression and anxiety are highly prevalent in most neurological disorders can have a major impact on the patient’s disability quality of life. However, mostly due to heterogeneity symptoms complexity underlying comorbidities, depression be difficult diagnose, resulting limited recognition undertreatment. The early detection treatment simultaneously with disorder is key avoiding deterioration further disability. Although neurologist should able identify treat initially, neuropsychiatry team available for severe cases those who unresponsive treatment. Neurologists also aware that neurodegenerative diseases, such as Alzheimer’s or Parkinson’s, different could develop at stages disease. options diseases include drugs, cognitive-behavioral therapy, somatic interventions, among others, but often, evidence-based efficacy results variable. Here, we review recent research diagnosis context disease, Parkinson’s strokes, aim identifying common approaches solutions its initial management by neurologist.

Язык: Английский

Процитировано

22

Psilocybin for the treatment of Alzheimer’s disease DOI Creative Commons
Siyi Zheng,

Rong Ma,

Yang Yang

и другие.

Frontiers in Neuroscience, Год журнала: 2024, Номер 18

Опубликована: Июль 10, 2024

Alzheimer’s disease (AD) stands as a formidable neurodegenerative ailment and prominent contributor to dementia. The scarcity of available therapies for AD accentuates the exigency innovative treatment modalities. Psilocybin, psychoactive alkaloid intrinsic hallucinogenic mushrooms, has garnered attention within neuropsychiatric realm due its established safety efficacy in treating depression. Nonetheless, potential therapeutic avenue remains largely uncharted. This comprehensive review endeavors encapsulate pharmacological effects psilocybin while elucidating existing evidence concerning mechanisms contributing positive impact on AD. Specifically, active metabolite psilocybin, psilocin, elicits through modulation 5-hydroxytryptamine 2A receptor (5-HT2A receptor). causes heightened neural plasticity, diminished inflammation, improvements cognitive functions such creativity, flexibility, emotional facial recognition. Noteworthy is psilocybin’s promising role mitigating anxiety depression symptoms patients. Acknowledging attendant adverse reactions, we proffer strategies aimed at tempering or effects. Moreover, broach ethical legal dimensions inherent exploration treatment. By traversing these avenues, We propose nuanced management disease.

Язык: Английский

Процитировано

7

Glutamate Efflux across the Blood–Brain Barrier: New Perspectives on the Relationship between Depression and the Glutamatergic System DOI Creative Commons
Benjamin F. Gruenbaum, Alexander Zlotnik, Amit Frenkel

и другие.

Metabolites, Год журнала: 2022, Номер 12(5), С. 459 - 459

Опубликована: Май 20, 2022

Depression is a significant cause of disability and affects millions worldwide; however, antidepressant therapies often fail or are inadequate. Current medications for treating major depressive disorder can take weeks months to reach efficacy, have troubling side effects, limited in their long-term capabilities. Recent studies identified new set glutamate-based approaches, such as blood glutamate scavengers, which the potential provide alternatives traditional antidepressants. In this review, we hypothesize involvement system development depression. We identify mechanisms underlying dysregulation, offering perspectives on therapeutic modalities depression with focus its relationship blood–brain barrier (BBB) permeability. Ultimately, conclude that diseases impaired BBB permeability, following stroke traumatic brain injury, neurogenerative diseases, should be considered pathway treatment. propose drugs scavengers further studied treatment these conditions.

Язык: Английский

Процитировано

27

Psychomotor Agitation DOI

Olusegun Adebisi Popoola,

Nidal Moukaddam

Cambridge University Press eBooks, Год журнала: 2025, Номер unknown, С. 123 - 133

Опубликована: Янв. 2, 2025

Язык: Английский

Процитировано

0

Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer’s Disease DOI Creative Commons
Muhammad Shahid Nadeem, Salman Hosawi,

Sultan Alshehri

и другие.

Biomolecules, Год журнала: 2021, Номер 11(11), С. 1635 - 1635

Опубликована: Ноя. 4, 2021

Autism spectrum disorder (ASD) and Alzheimer’s disease (AD) are neurodevelopmental neurodegenerative disorders affecting two opposite ends of life span, i.e., childhood old age. Both pose a cumulative threat to human health, with the rate incidences increasing considerably worldwide. In context recent developments, we aimed review correlated symptoms genetics, overlapping aspects in mechanisms pathogenesis ASD AD. Dementia, insomnia, weak neuromuscular interaction, as well communicative cognitive impairments, shared symptoms. A number genes proteins linked both have been tabulated, including MECP2, ADNP, SCN2A, NLGN, SHANK, PTEN, RELN, FMR1. Theories about role neuron development, processing, connectivity, levels neurotransmitters discussed. Based on literature, roles FMRP (Fragile X mental retardation protein), hnRNPC (heterogeneous ribonucleoprotein-C), IRP (Iron regulatory proteins), miRNAs (MicroRNAs), α-, β0, γ-secretases posttranscriptional regulation cellular synthesis processing APP (amyloid-β precursor protein) elaborated describe parallel routes AD pathogenesis. However, interactive genetic environmental factors, oxidative metal ion stress, mutations associated genes, alterations related pathways development needs further investigation.

Язык: Английский

Процитировано

32

Antidepressants in Alzheimer’s Disease: A Focus on the Role of Mirtazapine DOI Creative Commons
Ana Salomé Correia, Nuno Vale

Pharmaceuticals, Год журнала: 2021, Номер 14(9), С. 930 - 930

Опубликована: Сен. 16, 2021

Mirtazapine belongs to the category of antidepressants clinically used mainly in major depressive disorder but also obsessive-compulsive disorders, generalized anxiety, and sleep disturbances. This drug acts by antagonizing adrenergic α2, serotonergic 5-HT2 5-HT3 receptors. Neuropsychiatric symptoms, such as depression agitation, are strongly associated with Alzheimer's disease, reducing life quality these patients. Thus, it is crucial control For this purpose, drugs mirtazapine important other symptoms Indeed, despite some contradictory studies, evidence supports role regard. In review, we will focus on highlighting context.

Язык: Английский

Процитировано

30